AJP - Heart Calcium Transients and Cell-Sarcomere
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 285: H2001-H2012, 2003. First published July 24, 2003; doi:10.1152/ajpheart.00275.2003
0363-6135/03 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
285/5/H2001    most recent
00275.2003v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farias, M.
Right arrow Articles by Caffrey, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farias, M., III
Right arrow Articles by Caffrey, J. L.

Cardiac enkephalins attenuate vagal bradycardia: interactions with NOS-1-cGMP systems in canine sinoatrial node

Martin Farias, III, Keith Jackson, Michael Johnson, and James L. Caffrey

Department of Integrative Physiology, Cardiovascular Research Institute, University of North Texas Health Science Center, Fort Worth, Texas 76107

Submitted 7 April 2003 ; accepted in final form 18 July 2003

Endogenous opioids and nitric oxide (NO) are recognized modulators of cardiac function. Enkephalins and inhibitors of NO synthase (NOS) both produce similar interruptions in the vagal control of heart rate. This study was conducted to test the hypothesis that NO systems within the canine sinoatrial (SA) node facilitate local vagal transmission and that the endogenous enkephalin methionine-enkephalin-arginine-phenylalanine (MEAP) attenuates vagal bradycardia by interrupting the NOS-cGMP pathway. Microdialysis probes were inserted into the SA node, and they were perfused with nonselective (N{omega}-nitro-L-arginine methyl ester) and neuronal (7-nitroindazole) NOS inhibitors. The right vagus nerve was stimulated and both inhibitors gradually attenuated the resulting vagal bradycardia. The specificity of these inhibitions was verified by an equally gradual reversal of the inhibition with an excess of the NOS substrate L-arginine. Introduction of MEAP into the nodal interstitium produced a quickly developing but quantitatively similar interruption of vagal bradycardia that was also slowly reversed by the addition of L-arginine and not by D-arginine. Additional support for convergence of opioid and NO pathways was provided when the vagolytic effects of MEAP were also reversed by the addition of the NO donor S-nitroso-N-acetyl-penicillamine, the protein kinase G activator 8-bromo-cGMP, or the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine. MEAP and 7-nitroindazole were individually combined with the direct acting muscarinic agonist methacholine to evaluate potential interactions with muscarinic receptors within the SA node. MEAP and 7-nitroindazole were unable to overcome the bradycardia produced by methacholine. These data suggest that NO and enkephalins moderate the vagal control of heart rate via interaction with converging systems that involve the regulation of cAMP within nodal parasympathetic nerve terminals.

phosphodiesterase; nitric oxide; opioids; cAMP; heart rate; cardiac pacemaker



Address for reprint requests and other correspondence: J. L. Caffrey, Dept. of Integrative Physiology, Cardiovascular Research Institute, Univ. of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX 76107-2699 (E-mail: jcaffrey{at}hsc.unt.edu).




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. H. Deo, M. A. Barlow, L. Gonzalez, D. Yoshishige, and J. L. Caffrey
Cholinergic location of {delta}-opioid receptors in canine atria and SA node
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H829 - H838.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. H. Deo, S. Johnson-Davis, M. A. Barlow, D. Yoshishige, and J. L. Caffrey
Repeated {delta}1-opioid receptor stimulation reduces {delta}2-opioid receptor responses in the SA node
Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2246 - H2254.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Davis, S. H. Deo, M. Barlow, D. Yoshishige, M. Farias, and J. L. Caffrey
The monosialosyl ganglioside GM-1 reduces the vagolytic efficacy of {delta}2-opioid receptor stimulation
Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2318 - H2326.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
M. A. Barlow, S. Deo, S. Johnson, and J. L. Caffrey
Vagotonic effects of enkephalin are not mediated by sympatholytic mechanisms.
Experimental Biology and Medicine, April 1, 2006; 231(4): 387 - 395.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2003 by the American Physiological Society.